News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Nordic Nanovector: Updated Results From Phase 1/2 Trial Of Betalutin In Non-Hodgkin Lymphoma To Be Presented At American Society of Hematology Annual Meeting In December

11/3/2016 9:25:48 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Oslo, Norway, 3 November 2016

Nordic Nanovector ASA (OSE: NANO) announces that updated results and analysis from its ongoing Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in subjects with relapsed/refractory non-Hodgkin lymphoma (NHL) will be presented in a poster at the 58th Annual American Society of Hematology (ASH) meeting (3-6 December 2016 in San Diego, CA, USA).

The Lymrit 37-01 study is an ongoing Phase 1/2 open label, single injection ascending dose study investigating three dose levels of Betalutin® and different pre-dosing regimens in patients with relapsed NHL with the aim of identifying an optimal dose regimen to take into the pivotal Phase 2.

The poster will provide an update of safety and efficacy results (including duration of response) in the Lymrit 37-01 trial to those previously presented in April at the American Association of Cancer Research (AACR) annual meeting (21 patients) and to those noted in the abstract published by ASH today (abstract 1780), which includes data as of 8 August 2016 (date of submission of the abstract to ASH), based on 24 evaluable NHL patients from 36 patients enrolled at the time. See details on abstract 1780 below.

The poster will include the first available safety and efficacy results from patients enrolled into Arms 3 and 4 of the trial who received two different pre-dosing regimens prior to Betalutin® injection.

The ASH annual meeting is the premier event for scientific exchange in the field of hematology, attracting more than 20,000 attendees from all over the world. Typically, more than 5,000 scientific abstracts are submitted each year, and more than 3,000 abstracts are accepted for oral and poster presentations through an extensive peer review process.

Poster details

Abstract 1780

Abstract title: 177lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Authors: Kolstad, A et al.

Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I

Date/Time: Saturday, 3 December 2016, 5:30 PM - 7:30 PM (Pacific Std Time)

Location: San Diego Convention Center, Hall GH

Link to abstract:

Read at

Related News

comments powered by Disqus